New Document top_band
 
Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Read more on:    Healthcare | Januvia | Sun Pharma
Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of .

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Quick Links

 

Market News

Debt fund managers' careers at stake

At least 20% cuts in jobs anticipated with Budget change in tax treatment, with heavier impact on sales teams; sector mulls options

Uttarakhand to impose 2% entry tax on sugar

Move to stop units from buying commodity from Uttar Pradesh

Markets end at record closing highs

Sensex gained over 100 points and ended at 26147.33 while the Nifty ended 27 points higher at 7,795.75.

Sensex up 100 points; Infy, TCS up 2%

Sesnex is up 93 points at 26,119 and Nifty is up 18 points at 7,786 levels

Atul Limited soars over 10% on robust Q1 earnings

Q1 net profit up 48% at Rs 59.78 crore against Rs 40.45 crore in the corresponding quarter previous year.

Back to Top